PDF(Pubmed)
Abstract：
BACKGROUND: Ovarian cancer (OC) is the second most common gynecological tumor with the highest mortality rate worldwide. High FAM111B expression has been reported as a predictor of poor prognosis in other cancers, but its correlation with OC has not been reported.
METHODS: Immunohistochemistry of tissue microarrays was performed to detect FAM111B expression levels in 141 OC patient tissues. The prognostic value of FAM111B was determined by Kaplan-Meier survival analysis, and correlations between FAM111B expression and clinicopathologic features were investigated by the Clu-square test. The significance of FAM111B expression was verified bioinformatically using the Gene Expression Omnibus database. Protein-protein interaction were performed to explore downstream mechanisms of FAM111B in OC.
RESULTS: Among 141 OC patients, FAM111B was positively expressed in 87.23%, 58.16%, and 87.94%; and highly expressed in 8.51%, 17.02%, and 19.86%, as evaluated by cytoplasmic, nuclear, and combined cytoplasmic/nuclear staining. FAM111B expression was positively correlated with the expression of tumor protein markers KI67, EGFR, and PDL-1. Patients with high FAM111B expression had aggressive clinicopathologic features and shorter overall survival (P value 0.0428, 0.0050, 0.0029) and progression-free survival (P value 0.0251, 0.012, 0.0596) compared to the low FAM111B expression group for cytoplasmic, nuclear, and combined cytoplasmic/nuclear groups, respectively. These results were verified using patient data from the Gene Expression Omnibus. Seventeen genes co-expressed with FAM111B were primarily involved in \"negative regulation of histone modification\", \"hippo signaling\" and \"inner ear receptor cell differentiation\".
CONCLUSIONS: High FAM111B expression may serve as a novel prognostic predictor and molecular therapeutic target for OC.
METHODS: Immunohistochemistry of tissue microarrays was performed to detect FAM111B expression levels in 141 OC patient tissues. The prognostic value of FAM111B was determined by Kaplan-Meier survival analysis, and correlations between FAM111B expression and clinicopathologic features were investigated by the Clu-square test. The significance of FAM111B expression was verified bioinformatically using the Gene Expression Omnibus database. Protein-protein interaction were performed to explore downstream mechanisms of FAM111B in OC.
RESULTS: Among 141 OC patients, FAM111B was positively expressed in 87.23%, 58.16%, and 87.94%; and highly expressed in 8.51%, 17.02%, and 19.86%, as evaluated by cytoplasmic, nuclear, and combined cytoplasmic/nuclear staining. FAM111B expression was positively correlated with the expression of tumor protein markers KI67, EGFR, and PDL-1. Patients with high FAM111B expression had aggressive clinicopathologic features and shorter overall survival (P value 0.0428, 0.0050, 0.0029) and progression-free survival (P value 0.0251, 0.012, 0.0596) compared to the low FAM111B expression group for cytoplasmic, nuclear, and combined cytoplasmic/nuclear groups, respectively. These results were verified using patient data from the Gene Expression Omnibus. Seventeen genes co-expressed with FAM111B were primarily involved in \"negative regulation of histone modification\", \"hippo signaling\" and \"inner ear receptor cell differentiation\".
CONCLUSIONS: High FAM111B expression may serve as a novel prognostic predictor and molecular therapeutic target for OC.
摘要：
背景：卵巢癌（OC）是全球第二大最常见的妇科肿瘤，死亡率最高。据报道，FAM111B高表达是其他癌症预后不良的预测因子。但其与OC的相关性尚未报道。
方法：进行组织微阵列的免疫组织化学以检测141个OC患者组织中的FAM111B表达水平。通过Kaplan-Meier生存分析确定FAM111B的预后价值。FAM111B表达与临床病理特征之间的相关性通过Clu平方检验进行研究。FAM111B表达的重要性使用基因表达综合数据库进行生物信息学验证。进行蛋白质-蛋白质相互作用以探索OC中FAM111B的下游机制。
结果：在141名OC患者中，FAM111B阳性表达率为87.23%,58.16%,和87.94%；高表达为8.51%，17.02%,19.86%，根据细胞质评估，核,和结合的细胞质/核染色。FAM111B表达与肿瘤蛋白标志物KI67、EGFR、和PDL-1。与FAM111B低表达组相比，FAM111B高表达组具有侵袭性的临床病理特征和较短的总生存期（P值0.0428、0.0050、0.0029）和无进展生存期（P值0.0251、0.012、0.0596）。核,和细胞质/细胞核组合，分别。使用来自基因表达综合的患者数据验证了这些结果。与FAM111B共表达的17个基因主要参与“组蛋白修饰的负调控”，“河马信号”和“内耳受体细胞分化”。
结论：高FAM111B表达可能是OC的一个新的预后预测因子和分子治疗靶点。
方法：进行组织微阵列的免疫组织化学以检测141个OC患者组织中的FAM111B表达水平。通过Kaplan-Meier生存分析确定FAM111B的预后价值。FAM111B表达与临床病理特征之间的相关性通过Clu平方检验进行研究。FAM111B表达的重要性使用基因表达综合数据库进行生物信息学验证。进行蛋白质-蛋白质相互作用以探索OC中FAM111B的下游机制。
结果：在141名OC患者中，FAM111B阳性表达率为87.23%,58.16%,和87.94%；高表达为8.51%，17.02%,19.86%，根据细胞质评估，核,和结合的细胞质/核染色。FAM111B表达与肿瘤蛋白标志物KI67、EGFR、和PDL-1。与FAM111B低表达组相比，FAM111B高表达组具有侵袭性的临床病理特征和较短的总生存期（P值0.0428、0.0050、0.0029）和无进展生存期（P值0.0251、0.012、0.0596）。核,和细胞质/细胞核组合，分别。使用来自基因表达综合的患者数据验证了这些结果。与FAM111B共表达的17个基因主要参与“组蛋白修饰的负调控”，“河马信号”和“内耳受体细胞分化”。
结论：高FAM111B表达可能是OC的一个新的预后预测因子和分子治疗靶点。
